← Evidence map

ArticleDiscover oncology2026

Integrated FHIT and IDH2 biomarker profiling predicts lethal sensitivity to DCPS inhibition in Acute Myeloid Leukemia and Myelodysplastic syndrome.

Francesca Grassi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Integrated FHIT and IDH2 biomarker profiling predicts lethal sensitivity to DCPS inhibition in Acute Myeloid Leukemia and Myelodysplastic syndrome. | OpenQuestion